CD4 and neutropenia: Although there seems to be an increased risk of clinical infections after RTX treatment, the rate of infection is poorly correlated with the types of immune diseases and is closely correlated with low hypogammaglobulinemia, neutropenia, CD4+ T cell dysfunction, etc. (73).